HCAT Stock Recent News

Despite a 50% drop in HCAT's stock price, the company shows significant growth, reporting $307M in revenue and $26M in adjusted EBITDA for 2024. Health Catalyst focuses on efficiency, exiting lower-margin segments, and pushing AI-driven efficiencies, aiming for improved margins and profitability in 2025. The company forecasts strong growth with 40 new platform clients in 2025 and expects $335M in revenue, trading at a significant discount compared to industry peers.

Investors need to pay close attention to Health Catalyst (HCAT) stock based on the movements in the options market lately.

SALT LAKE CITY , March 11, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced it has repurchased shares of its common stock ("Common Stock") in an aggregate amount of approximately $5 million. These repurchased shares were acquired between March 3, 2025, and March 10, 2025, as part of Health Catalyst's existing share repurchase program approved by its board of directors on August 2, 2022, which authorized repurchases of up to $40 million of Common Stock.

SALT LAKE CITY , Feb. 27, 2025 /PRNewswire/ -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced a multi-year agreement with Signature Healthcare, an integrated healthcare delivery system serving Southeastern Massachusetts. Signature Healthcare is collaborating with Health Catalyst to integrate data resource queries and unlock referral-related data powered by Health Catalyst Ignite™, a modern data and analytics ecosystem.

Health Catalyst, Inc. (NASDAQ:HCAT ) Q4 2024 Earnings Call Transcript February 26, 2025 5:00 PM ET Company Participants Jack Knight - Vice President, Investor Relations Dan Burton - Chief Executive Officer Dan LeSueur - Chief Operating Officer Jason Alger - Chief Financial Officer Conference Call Participants Jared Haase - William Blair Anne Samuel - JPMorgan Jessica Tassan - Piper Sandler Sameer Patel - Evercore ISI John Pinney - Canaccord Genuity Daniel Grosslight - Citi David Larsen - BTIG Scott Schoenhaus - KeyBanc Stan Berenshteyn - Wells Fargo Operator Welcome to the Health Catalyst's Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode and the floor will be open for your questions following the presentation.

Although the revenue and EPS for Health Catalyst (HCAT) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Health Catalyst (HCAT) came out with quarterly earnings of $0.04 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.02 per share a year ago.

SALT LAKE CITY, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today reported financial results for the quarter and year ended December 31, 2024.

SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Dan Burton, Chief Executive Officer, Jason Alger, Chief Financial Officer, Dan LeSueur, Chief Operating Officer, and Jack Knight, Vice President of Investor Relations, will participate in the Raymond James & Associates' 46th Annual Institutional Investors Conference, in Orlando, FL. Health Catalyst will host a fireside chat presentation on Tuesday, March 4, 2025, at 1:40 p.m.

SALT LAKE CITY, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced that Dan Burton, Chief Executive Officer, Jason Alger, Chief Financial Officer, and Dan LeSueur, Chief Operating Officer, will participate in the BTIG at Snowbird: MedTech, Digital Health, Life Science & Diagnostic Tools Conference, in Snowbird, UT, on Tuesday, February 11, 2025.